Literature DB >> 31930426

Increased Expression of Delta-like Ligand 4 in Mycosis Fungoides.

Hikari Boki1, Tomomitsu Miyagaki, Yuki Shono, Hiroaki Kamijo, Tomonori Oka, Hiraku Suga, Yoshihide Asano, Makoto Sugaya, Shinichi Sato.   

Abstract

In many malignancies, dysregulation of the Notch pathways, composed of 4 Notch receptors (Notch1-4) and 5 Notch ligands (Jagged1-2, Delta-like ligand-1, 3-4), is associated with their development. In mycosis fungoides, interaction between Notch1 and Jagged1 is known to activate the Notch pathways and promote the proliferation of tumour cells. However, the involvement of other Notch ligands has not been reported. This study investigated the roles of Delta-like ligand 4 in mycosis fungoides. Delta-like ligand 4 mRNA levels in lesional skin of patients with mycosis fungoides were significantly elevated compared with those of normal controls, and correlated with disease-specific mortality. Immunohistochemical staining demonstrated prominent expression of Delta-like ligand 4 on vascular endothelial cells and tumour cells in mycosis fungoides lesional skin. In addition, Delta-like ligand 4 augmented the proliferation of cutaneous T-cell lym-phoma cell lines. These results suggest that enhanced Delta-like ligand 4 expression may contribute directly to the progression of mycosis fungoides through proliferating tumour cells.

Entities:  

Keywords:  Notch homolog 1; cutaneous T-cell lymphoma; mycosis fungoides; delta-like ligand 4

Mesh:

Substances:

Year:  2020        PMID: 31930426      PMCID: PMC9128970          DOI: 10.2340/00015555-3402

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  25 in total

1.  Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma.

Authors:  Maria R Kamstrup; Lise Mette Rahbek Gjerdrum; Edyta Biskup; Britt Thyssing Lauenborg; Elisabeth Ralfkiaer; Anders Woetmann; Niels Ødum; Robert Gniadecki
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

Review 2.  The pathogenesis of mycosis fungoides.

Authors:  Michael Girardi; Peter W Heald; Lynn D Wilson
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

3.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

4.  Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

Authors:  Mark J McKeage; Dusan Kotasek; Ben Markman; Manuel Hidalgo; Michael J Millward; Michael B Jameson; Dean L Harris; Robert J Stagg; Ann M Kapoun; Lu Xu; Brett G M Hughes
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

5.  Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.

Authors:  Julia J Scarisbrick; H Miles Prince; Maarten H Vermeer; Pietro Quaglino; Steven Horwitz; Pierluigi Porcu; Rudolf Stadler; Gary S Wood; Marie Beylot-Barry; Anne Pham-Ledard; Francine Foss; Michael Girardi; Martine Bagot; Laurence Michel; Maxime Battistella; Joan Guitart; Timothy M Kuzel; Maria Estela Martinez-Escala; Teresa Estrach; Evangelia Papadavid; Christina Antoniou; Dimitis Rigopoulos; Vassilki Nikolaou; Makoto Sugaya; Tomomitsu Miyagaki; Robert Gniadecki; José Antonio Sanches; Jade Cury-Martins; Denis Miyashiro; Octavio Servitje; Cristina Muniesa; Emilio Berti; Francesco Onida; Laura Corti; Emilia Hodak; Iris Amitay-Laish; Pablo L Ortiz-Romero; Jose L Rodríguez-Peralto; Robert Knobler; Stefanie Porkert; Wolfgang Bauer; Nicola Pimpinelli; Vieri Grandi; Richard Cowan; Alain Rook; Ellen Kim; Alessandro Pileri; Annalisa Patrizi; Ramon M Pujol; Henry Wong; Kelly Tyler; Rene Stranzenbach; Christiane Querfeld; Paolo Fava; Milena Maule; Rein Willemze; Felicity Evison; Stephen Morris; Robert Twigger; Rakhshandra Talpur; Jinah Kim; Grant Ognibene; Shufeng Li; Mahkam Tavallaee; Richard T Hoppe; Madeleine Duvic; Sean J Whittaker; Youn H Kim
Journal:  J Clin Oncol       Date:  2015-10-05       Impact factor: 44.544

6.  MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.

Authors:  David W Jenkins; Sarah Ross; Margaret Veldman-Jones; Ian N Foltz; Brandon C Clavette; Kathy Manchulenko; Cath Eberlein; Jane Kendrew; Philip Petteruti; Song Cho; Melissa Damschroder; Li Peng; Dawn Baker; Neil R Smith; Hazel M Weir; David C Blakey; Vahe Bedian; Simon T Barry
Journal:  Mol Cancer Ther       Date:  2012-06-07       Impact factor: 6.261

7.  TOX expression in different subtypes of cutaneous lymphoma.

Authors:  Sohshi Morimura; Makoto Sugaya; Hiraku Suga; Tomomitsu Miyagaki; Hanako Ohmatsu; Hideki Fujita; Yoshihide Asano; Yayoi Tada; Takafumi Kadono; Shinichi Sato
Journal:  Arch Dermatol Res       Date:  2014-09-13       Impact factor: 3.017

8.  Higher notch expression implies poor survival in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

Authors:  Jianbin Ye; Junjie Wen; Yunshan Ning; Yan Li
Journal:  Pancreatology       Date:  2018-10-01       Impact factor: 3.996

Review 9.  Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer.

Authors:  Rebecca A Previs; Robert L Coleman; Adrian L Harris; Anil K Sood
Journal:  Clin Cancer Res       Date:  2014-11-11       Impact factor: 12.531

10.  A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.

Authors:  Elena Gabriela Chiorean; Patricia LoRusso; Robert Matthew Strother; Jennifer R Diamond; Anne Younger; Wells A Messersmith; Lieve Adriaens; Liming Liu; Richard J Kao; Albert Thomas DiCioccio; Ana Kostic; Russell Leek; Adrian Harris; Antonio Jimeno
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.